Germany Point-Of-Care Molecular Diagnostics Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Point-of-Care Molecular Diagnostics Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask Prism AI anything about the point-of-care molecular diagnostics market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
Germany point-of-care molecular diagnostics market highlights
- The Germany point-of-care molecular diagnostics market generated a revenue of USD 420.5 million in 2024 and is expected to reach USD 737.5 million by 2033.
- The Germany market is expected to grow at a CAGR of 6.5% from 2025 to 2033.
- In terms of segment, infectious diseases was the largest revenue generating application in 2024.
- Oncology is the most lucrative application segment registering the fastest growth during the forecast period.
Point-of-care molecular diagnostics market data book summary
| Market revenue in 2024 | USD 420.5 million |
| Market revenue in 2033 | USD 737.5 million |
| Growth rate | 6.5% (CAGR from 2025 to 2033) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Oncology |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
| Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
Other key industry trends
- In terms of revenue, Germany accounted for 5.1% of the global point-of-care molecular diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany point-of-care molecular diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 394.5 million by 2033.
Germany holds a considerable share of Europe’s point-of-care molecular diagnostics market, owing primarily to its large geriatric population. According to the UN’s population data, one in every 20 people in Germany is over 80 years, which is expected to increase to one in every six individuals by 2050.
Problems with the increasing geriatric population include a higher risk of chronic diseases, such as cardiovascular diseases, diabetes, and neurovascular disorders, due to the onset of senescence & decreased immunity levels.
Rapid diagnostic techniques such as point-of-care molecular diagnostic devices are useful for this demographic. Key manufacturer such as Roche is strengthening its operations in Germany, which is expected to boost the point-of-care molecular diagnostics market.
No credit card required*
Publish Date: Aug 05, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Point-Of-Care Molecular Diagnostics Market Scope
Point-Of-Care Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Nova Biomedical | View profile | 501-1000 | Waltham, Massachusetts, United States, North America | www.novabio.us |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Nipro Corp | View profile | 39,713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | www.nipro.co.jp |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
Germany Point-of-Care Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Point-of-Care Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 49.85% in 2024.
Horizon Databook has segmented the Germany point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2021 to 2033.
Germany holds a considerable share of Europe’s point-of-care molecular diagnostics market, owing primarily to its large geriatric population. According to the UN’s population data, one in every 20 people in Germany is over 80 years, which is expected to increase to one in every six individuals by 2050.
Problems with the increasing geriatric population include a higher risk of chronic diseases, such as cardiovascular diseases, diabetes, and neurovascular disorders, due to the onset of senescence & decreased immunity levels.
Rapid diagnostic techniques such as point-of-care molecular diagnostic devices are useful for this demographic. Key manufacturer such as Roche is strengthening its operations in Germany, which is expected to boost the point-of-care molecular diagnostics market.
- Germany Point-Of-Care Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Prenatal Testing
- Endocrinology
- Other Applications
- Hematology
- Infectious Diseases
- Germany Point-Of-Care Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2021-2033)
- PCR-based
- Genetic Sequencing based
- Hybridization based
- Microarray based
- Germany Point-Of-Care Molecular Diagnostics Market Test Location Outlook (Revenue, USD Million , 2021-2033)
- OTC
- POC
- Germany Point-Of-Care Molecular Diagnostics Market End-use Outlook (Revenue, USD Million , 2021-2033)
- Decentralised Labs
- Hospitals
- Home care
- Assisted Living Healthcare Facilities
- Others
Reasons to subscribe to Point-of-Care Molecular Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Point-of-Care Molecular Diagnostics Market Outlook databook
- Our clientele includes a mix of Point-of-Care Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany Point-of-Care Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Germany Point-of-Care Molecular Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Germany Point-Of-Care Molecular Diagnostics Market, 2021-2033 (US$M)
Germany Application - Point-of-care Molecular Diagnostics Market Statistics, 2024 - 2033 (US$M)
